{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04342325",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CAMCR013"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "jRCT2043200002",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Japan Registry of Clinical Trials"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Nagoya University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "The Clinical Trial of ADR-001 for IgA Nephropathy",
      "OfficialTitle": "Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 15, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 31, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 31, 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 8, 2020",
      "StudyFirstSubmitQCDate": "April 10, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 13, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 10, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 12, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Shoichi Maruyama MD PhD",
        "ResponsiblePartyInvestigatorTitle": "Professor at Department of Nephrogy, Graduate school of Medicine",
        "ResponsiblePartyInvestigatorAffiliation": "Nagoya University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Nagoya University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Rohto Pharmaceutical Co., Ltd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Glomerulonephritis , IGA"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "3 + 3 dose escalation study design",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "ADR-001",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous infusion of ADR-001 (Mesenchymal stem cell)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: infusion of ADR-001 (Mesenchymal stem cell)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "infusion of ADR-001 (Mesenchymal stem cell)",
            "InterventionDescription": "Once or twice with two week interval at a dose of 100 x 10 ^ 6 cells.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "ADR-001"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of adverse events",
            "PrimaryOutcomeDescription": "Any adverse events are summarized.",
            "PrimaryOutcomeTimeFrame": "until 6 weeks after first administration"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Clinical remission (proteinuria, hematuria)",
            "SecondaryOutcomeDescription": "Ratio and time frame to achieve remission are summarized.",
            "SecondaryOutcomeTimeFrame": "at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration"
          },
          {
            "SecondaryOutcomeMeasure": "Proteinuria",
            "SecondaryOutcomeDescription": "Change from baseline value and ratio to achieve threshold are summarized.",
            "SecondaryOutcomeTimeFrame": "at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration"
          },
          {
            "SecondaryOutcomeMeasure": "Hematuria",
            "SecondaryOutcomeDescription": "Change from baseline value and ratio to achieve threshold are summarized.",
            "SecondaryOutcomeTimeFrame": "at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration"
          },
          {
            "SecondaryOutcomeMeasure": "Estimated glomerular filtration rate (eGFR)",
            "SecondaryOutcomeDescription": "Change from baseline value are summarized.",
            "SecondaryOutcomeTimeFrame": "at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nIgA nephropathy diagnosed by renal biopsy.\n\nMeet any of the following criteria.\n\ni. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min / 1.73m^2 or more even if corticosteroids are used for 6 months or more before screening.\n\nii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m^2 or more and less than 60 mL / min / 1.73 m^2 at screening even if corticosteroids are used for 6 months or more before screening.\n\niii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and eGFR of 20 mL / min / 1.73m^2 or more and 60 mL / min / 1.73m^2 or urine protein of 1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m^2 or more and less than 30 mL / min / 1.73m^2.\n\nOver 20 years old.\nAble to provide informed consent.\n\nHowever, in the first cohort, only 2) -i is applied in the selection criteria 2), and in the second cohort, 2) -i, ii, and iii are applied.\n\nExclusion Criteria:\n\nNephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.\nStart or increase drug therapy for IgA nephropathy with corticosteroids, immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs, anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal tonsillectomy within 6 months.\nTreatment with other cells.\nParticipated within 3 months or participating in other clinical trials .\nPenal transplantation within 3 years or scheduled.\nDiabetics not well controlled.\nMalignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.\nSuspected of active infection.\nPositive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.\nHistory of severe hypersensitivity or anaphylactic reaction.\nAllergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide (DMSO).\nSerious complications not related to IgA nephropathy.\nBleeding or may bleed, shallow days after surgery or trauma to the central nervous system, history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia Previous patient.\nDuring pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Shoichi Maruyama, MD, PhD",
            "OverallOfficialAffiliation": "Nagoya University",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Kasugai Municipal Hospital",
            "LocationCity": "Kasugai",
            "LocationState": "Aichi",
            "LocationZip": "486-8510",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Nagoya University Hospital",
            "LocationCity": "Nagoya",
            "LocationState": "Aichi",
            "LocationZip": "566-8560",
            "LocationCountry": "Japan"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000005921",
            "ConditionMeshTerm": "Glomerulonephritis"
          },
          {
            "ConditionMeshId": "D000005922",
            "ConditionMeshTerm": "Glomerulonephritis, IGA"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007674",
            "ConditionAncestorTerm": "Kidney Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000009393",
            "ConditionAncestorTerm": "Nephritis"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8184",
            "ConditionBrowseLeafName": "Glomerulonephritis, IGA",
            "ConditionBrowseLeafAsFound": "Glomerulonephritis, IGA",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8183",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafAsFound": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11490",
            "ConditionBrowseLeafName": "Nephritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3008",
            "ConditionBrowseLeafName": "IgA Nephropathy",
            "ConditionBrowseLeafAsFound": "Glomerulonephritis, IGA",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2525",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafAsFound": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18269",
            "InterventionBrowseLeafName": "Immunoglobulins, Intravenous",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9270",
            "InterventionBrowseLeafName": "Immunoglobulin A",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}